The National Clinical Research Center for Blood Diseases (hereinafter referred to as "the Center" ) is the national clinical medical research center that was jointly issued by the Ministry of Science and Technology, the National Health Commission, the Logistics Support Department of the Central Military Commission and the National Medical Products Administration in May, 2019.

The Center aims to enhance the basic and clinical research on hematological diseases, improve the clinical research, and promote the clinical translation. To address the needs of hematological disease prevention and control in China, the Center launched sub-centers and collaborative innovation centers, and has developed a collaborative innovation network that spans the entire country. The medical science and technology innovation system, which integrates the research, clinical practices, and translational network nationwide, will expedite the innovation breakthroughs and advancement in the field of hematology. As of September 2022, 28 sub-centers have been authorized, encompassing 18 provinces and cities nationwide.

Combining nationally recognized clinical excellence, the Center focuses on the development of cutting-edge technologies such as cellular immunotherapy, stem cell and gene therapy, and the integration of Chinese traditional medicine for the diagnosis and treatment of hematological diseases, and has achieved series of milestones.